Last reviewed · How we verify
TAK-935
At a glance
| Generic name | TAK-935 |
|---|---|
| Also known as | OV935, Soticlestat |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Soticlestat in Adults and Children With Rare Epilepsies (PHASE2)
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome (PHASE3)
- A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine (PHASE3)
- A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome (PHASE3)
- A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience (PHASE1)
- A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome (PHASE3)
- A Study of Soticlestat Tablets in Healthy Adults (PHASE1)
- A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |